PIERLUIGI MELONI

Dr. PIERLUIGI MELONI

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Therapeutic Advances in Musculoskeletal Disease
Verified
Journal Article
Open access
PDF file
GEGian Luca Erre
Gian Luca Erre
FCFloriana Castagna
Floriana Castagna
ASAssunta Sauchella
Assunta Sauchella
PMPIERLUIGI MELONI
PIERLUIGI MELONI
Arduino MangoniArduino Mangoni
Arduino Mangoni
GIANPAOLO VIDILIGIANPAOLO VIDILI
GIANPAOLO VIDILI
The independent association between hepatic steatosis and rheumatoid arthritis is poorly defined. The presence of moderate to severe steatosis was assessed, using liver ultrasonography, in 364 consecutive non-diabetic subjects (223 patients with rheumatoid arthritis and 141 age- and sex-matched healthy controls). Adjusted multiple regression analysis was performed to explore the association between rheumatoid arthritis and moderate to severe steatosis in the overall sample and identify independent risk factors in the rheumatoid arthritis subgroup. The prevalence of moderate to severe steatosis in the overall sample was 31.3%, with a significantly higher prevalence in patients with rheumatoid arthritis than healthy controls (38.7% versus 19.7%, p < 0.0001). After adjustment for sex, age, cholesterol, triglycerides, body mass index, waist, hypertension and smoke, rheumatoid arthritis remained significantly associated with moderate to severe steatosis [odds ratio (95% confidence interval) = 2.24 (1.31, 3.84); p = 0.003]. In the rheumatoid arthritis group, male sex, higher body mass index, higher triglycerides concentrations and higher cumulative dosage of methotrexate [odds ratio (95% confidence interval) = 1.11 (1.01, 1.23); p = 0.026] were significantly associated with moderate to severe steatosis, while systemic inflammation, disease activity, use of steroids and biologics were not. Rheumatoid arthritis is independently associated with moderate to severe steatosis, with male sex, higher body mass index and cumulative dose of methotrexate being predisposing factors. Further prospective studies are warranted to confirm our findings and to investigate the effect of steatosis on liver outcomes in the rheumatoid arthritis population.

Verified
Journal Article
Open access
PDF file
GIANPAOLO VIDILIGIANPAOLO VIDILI
GIANPAOLO VIDILI
MAMARCO ARRU
MARCO ARRU
PMPIERLUIGI MELONI
PIERLUIGI MELONI
Giuliana SolinasGiuliana Solinas
Giuliana Solinas
SASebastiana Atzori
Sebastiana Atzori
IMIvana Maida
Ivana Maida
Background: Transient Elastography (TE) is widely regarded as the most reliable non-invasive method for evaluating liver fibrosis. Recently, new techniques such as 2D Shear Wave Elastography (2D-SWE) have been developed. This study aimed to evaluate the correlation between TE and 2D-SWE in patients with HCV-related chronic liver disease and to redefine the cut-off values of 2D-SWE for predicting different stages of fibrosis based on our results. Methods: Both TE (Fibroscan, Echosens, Paris, France) and 2D-SWE (SuperSonic Imagine) were performed simultaneously in 170 patients, including those with active and eradicated HCV infection. Spearman’s rank correlation coefficient was used to assess the correlation between the two measurements, and the concordance between the assigned METAVIR classes was calculated using Cohen’s kappa coefficient. ROC curves were constructed to determine the optimal cut-off values for 2D-SWE. Results: Ten patients were excluded for invalid measurements. In the remaining 160 patients, TE and 2D-SWE demonstrated a high correlation (ρ = 0.83, p < 0.0001) and good agreement in METAVIR classification (k = 0.74). The optimal cut-off values identified for 2D-SWE were as follows: ≥ 7 kPa for F ≥ 2, ≥ 8.3 kPa for F ≥ 3, and ≥ 9.4 kPa for F4. Conclusions: 2D-SWE is a viable alternative to TE for patients with HCV-related chronic liver disease. Our data suggest that the currently accepted 2D-SWE cut-off values for cirrhosis (F4) should be reconsidered and potentially lowered.

19 February 2026 in Infectious Agents and Cancer
Verified
Journal Article
Open access
PDF file
MCMarco Cascella
Marco Cascella
CPCesare Pane
Cesare Pane
MPMarcello Di Pumpo
Marcello Di Pumpo
ESEnrico Sebastiani
Enrico Sebastiani
MBMartino Bussa
Martino Bussa
VGVincenza Granata
Vincenza Granata
Digital health technologies (DHTs), including digital therapeutics (DTx), are revolutionizing patient care by enabling the prevention, management, and trea

28 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MCMarco Cascella
Marco Cascella
CPCesare Pane
Cesare Pane
MPMarcello Di Pumpo
Marcello Di Pumpo
ESEnrico Sebastiani
Enrico Sebastiani
MBMartino Bussa
Martino Bussa
VGVincenza Granata
Vincenza Granata
Digital health technologies (DHTs), including digital therapeutics (DTx), are revolutionizing patient care by enabling the prevention, management, and treatment of medical conditions. These tools comprise care delivery mobile applications, wearable devices, and cloud platforms for capturing real-time data and enabling remote monitoring. DTx also encompasses artificial intelligence (AI) and machine learning algorithms, as well as AI agents and digital twins (DTs) for clinical decision-making and predictive analytics. Evidence supports the effectiveness of DHT strategies across different clinical fields. For example, wearable and remote patient monitoring technologies enable continuous assessment and personalized feedback in cardiology and neurology. Additionally, AI-enabled devices are mostly implemented for continuous monitoring of glucose levels. However, several key challenges remain. Persistent gender and social biases in datasets and algorithms raise ethical concerns, particularly for underrepresented groups and pediatric populations. Mitigation strategies include regulatory frameworks, explainable AI, and trustworthy AI ecosystems. This narrative review synthesizes current evidence, highlights implementation barriers, and proposes recommendations to enhance inclusivity, interoperability, and real-world evaluation of these technologies. Applications of DHT in animals within the one digital health framework are also discussed.